Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Denver news in your inbox

Catch up on the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Des Moines news in your inbox

Catch up on the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Minneapolis-St. Paul news in your inbox

Catch up on the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tampa Bay news in your inbox

Catch up on the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Charlotte news in your inbox

Catch up on the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Illustration: Sarah Grillo/Axios

The Food and Drug Administration released a statement last night throwing cold water, for now at least, on ideas to shake up coronavirus vaccine dosing regimens in order to stretch limited supplies.

What's happening: Some experts have been pushing ideas like delaying the administration of second doses or halving the vaccine dosage given in order to vaccinate more people sooner, but none of these methods have been tested in clinical trials.

What they're saying: "These are all reasonable questions to consider and evaluate in clinical trials. However, at this time, suggesting changes to the FDA-authorized dosing or schedules of these vaccines is premature and not rooted solidly in the available evidence," the FDA said in a statement.

  • "Without appropriate data supporting such changes in vaccine administration, we run a significant risk of placing public health at risk, undermining the historic vaccination efforts to protect the population from COVID-19."

Go deeper: America's vaccine rollout: What went wrong

Go deeper

15 hours ago - Health

Bill and Melinda Gates warn of "immunity inequality"

Bill and Melinda Gates at a Goalkeepers event in 2018. Photo: Ludovic Marin/AFP via Getty Images

Bill and Melinda Gates warned in their annual letter Wednesday that the lasting legacy of the coronavirus pandemic could be "immunity inequality" — a wide and deadly gap between wealthy people, with easy access to coronavirus vaccines, and everyone else.

Why it matters: As long as there are large swaths of the world that can't get vaccinated, they warned, it will be impossible to get the pandemic under control.

15 hours ago - Health

One year of the coronavirus

One year ago today, a novel coronavirus was barely beginning to catch the public's eye. There were just over 2,000 confirmed cases worldwide, mostly in China, and five cases in the U.S.

The big picture: The sea of red says it all. Today, there have been over 100 million cases worldwide, led by the U.S. with 25 million.

12 hours ago - Sports

Europe's 20 richest soccer clubs report 12% revenue hit due to coronavirus

Data: Deloitte; Table: Andrew Witherspoon/Axios

Europe's 20 most lucrative soccer clubs earned $9.97 billion in 2019-20, down from $11.31 billion the previous year, per Deloitte's 24th annual Football Money League report.

The state of play: That 12% drop was driven mostly by broadcast revenue deferrals, comprising a $1.14 billion decrease year-over-year. Matchday revenue also fell drastically, down $312.6 million.

You’ve caught up. Now what?

Sign up for Mike Allen’s daily Axios AM and PM newsletters to get smarter, faster on the news that matters.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!